6-MP studie.

Identification of predictive parameters for 6-MP response in AML patients.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON28582

Enrollment

Registered

2009-05-07

Start date

2008-06-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid leukemia Acute myeloide leukemie

Interventions

Peripheral blood and bone marrow cells will be collected before and during treatment with 6-MP.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age >18 years; 2. Diagnosed with (relapsing) AML and not eligible for intensive chemotherapy.

Exclusion criteria

Exclusion criteria: Ineligible or not willing to perform the proposed tests.

Design outcomes

Primary

Measure	Time frame
1. Expression of multidrug-resistance genes, nuclear receptors and in vitro susceptibity for 6-MP; 2. Changes in the lymphoid compartment during treatment with 6-MP; 3. HLA-type; 4. Clinical response on treatment with 6-MP.	—

Contacts

Public ContactE. Vellenga

University Medical Center Groningen (UMCG), Department of Hematology, P.O. Box 30001

e.vellenga@int.umcg.nl+31 (0)50 3612354

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)